Atrial fibrillation management summary
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Atrial fibrillation management summary

  • 1,082 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
1,082
On Slideshare
1,081
From Embeds
1
Number of Embeds
1

Actions

Shares
Downloads
44
Comments
0
Likes
0

Embeds 1

https://learnonline.nku.edu 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Management of Atrial Fibrillation ♦ Assess the need to convert to sinus rhythmCauses of Atrial Fibrillation Physical ExamCardiac ♦ Valvular dz – MR, MS ♦ Sick sinus syndrome ♦ confirm AF (4 signs) ♦ IHD ♦ Post-cardiac surgery o IR IR pulse ♦ HPT ♦ Peri-/myo-carditis o Single flicker JVP - absence of ‘a’ wave ♦ Post MI ♦ Pre-excitation syndrome o pulse deficit ♦ CCF ♦ Acute pul. Embolism o varying loudness of 1st heart sound ♦ ASD ♦ Lone AF (no known ♦ signs of underlying causes of AF– BP, goiter and signs of thyrotoxicosis, ♦ Cardiomyopathy etiology or structural heart auscultation for murmurs (MR/MS) dz. Dx of exclusion) ♦ complications – CCF, previous strokeNon-Cardiac ♦ Hyperthyroidism ♦ DM ♦ Sepsis esp pneumonia ♦ Alcohol Investigations ECG ♦ to document AF, any evidence of MI, LVH/LAHMorbidities of AF CXR ♦ chamber size, heart failure♦ ↓ cardiac output – malaise and effort intolerance FBC♦ aggravation of MI and heart failure U/E♦ ↑ risk of Thromboembolism and stroke TFT ♦ hyperthyroidism Transthoracic ♦ structural HD (CMP, valvular dz, intracardiac shunt, pericardialTypes of AF: echocardiogram HDz),♦ 1st detected episode - may not need tx if episode is brief/ known reversible cause (TTE) ♦ chamber sizes♦ Acute AF – detected within 24-48h, has high chance of pharm/electrical cardioversion ♦ LV size and function.♦ Paroxysmal AF – AF lasting less than 7 days Additional Invxs♦ Persistent AF – >7 days 24h Holter ♦ Quantify freq & duration of symptomatic & asymp. AF episodes♦ Permanent AF – previous attempts to restore sinus rhythm have failed/ AF lasted >1y. ♦ Look for sinus node dysf(x) or sick sinus syndrome The probability of successful cardioversion is very low ♦ Assess adequacy of rhythm or rate control ♦ Assess time of onset of AF (eg night in vagally-mediated AF)Clinical Presentations ♦ Identify PTs with frequent atrial ectopics & nonsustained atrial♦ Palpitations tachycardia suitable for catheter ablation♦ CP Transesophageal ♦ Gives better visualization of LA thrombus cf TTE)♦ Dyspnoea echocardiogram ♦ Use before elective cardioversion in PTs w/o prior 3wks♦ Fatigue (TEE) warfarin♦ Light headedness Exercise stress test ♦ Assess PT with AF ppted by exertion, IHD or MI♦ Syncope ♦ Routinely done for PTs ≥40YO or with significant coronary risk♦ Cxs of AF – heart failure, haemodynamic impairments, stroke factors.♦ Asymptomatic (25%) Electrophysiological ♦ For PTs w hx of syncope to exclude sick sinus syndrome and study (EPS) Wolff-Parkinson-White syndromeEvaluation of AF♦ stable or unstable Management of AF:♦ confirm diagnosis of AF with 12 lead ECG ♦ Aims: • Improve symptoms♦ classify type of AF o Control ventricular rate • Reduce TE stroke risk♦ determine underlying cause/factors contributing to AF (eg structural and ischaemic o Reestablish sinus rhythm • Prevent cardiac remodeling HDz, estimating LVEF, valvular HDz, CMP, HPT) o Anticoagulate to prevent Thromboembolism and hence HFailure & CMP♦ look for complications of AF♦ determine risk of future complications, i.e. stroke, from AF Unstable: o HTN/ old age/ IHD/ heart failure / previous stroke/ DM o immediate sync. Cardioversion♦ Assess adequacy of control of ventricular rate during AF o f/u with anticoagulation therapy for 4 weeks
  • 2. Stable: a) Acute AF (<48h) ♦ Can be cardioverted (pharm/electrical) without prior long-term anticoagulation Rhythm Control: ♦ Give IV heparin before proceeding ♦ Spontaneous cardioversion occurs in 50-70% of PTs w/in 24 to 48 hrs, but unlikely to ♦ And switch to oral, maintain INR at 2-3 for 4 weeks whatever the outcome occur if AF persisted for > a week. Drug/electrical cardioversion will be necessary. ♦ Success rate of cardioversion decrease as duration of AF increase, therefore perform b) Persistent/ Recurrent Paroxysmal AF early If minimal symptoms, ♦ Problems: failure in maintenance of sinus rhythm in >50% of PTs, significant SE of 1) Rate control drugs used o Beta-blocker o Ca blockers e.g. diltiazem/ verapamil ♦ Pharmacological Cardioversion: o Digoxin (esp if concurrent HF) Drug Comments SE o Sotalol Class IC arrhythmics ♦ Contraindications ♦ conversion to atrial flutter 2) Assess for risk of thromboembolism and anticoagulate as necessary (propafenone 300- - IHD ♦ ventricular tachycardia This is the recommended management for most patients, unless acute onset (<48h), or 600mg PO stat, - CCF ♦ enhanced AV nodal symptomatic, or complicated flecainide150-200mg - Lt vent dysf(x) conduction PO stat) - major conduction ♦ CCF disturbances c) Symptoms/ complications (e.g. syncope, heart failure, stroke) Amiodarone ♦ Takes days to wks for onset ♦ Hepatotoxic ♦ Rate control initially followed by cardioversion, with anticoagulation (600-800mg/day PO) ♦ Safe for PT with structural heart ♦ Thyroid dysfunction ♦ Then, o anticoagulate for 3 weeks with warfarin (keep INR 2-3) before cardioversion dz or heart failure ♦ GI upset ♦ Monitor LFT & TFT 6 mthly for SE ♦ Bradycardia ♦ Amiodarone ♦ Flecainide ♦ Torsades de pointes ♦ Propafenone ♦ polyneuropathy o Alternatively, do TEE to look for LA thrombus. If none, give IV Heparin and Dofetilide & ibutilide ♦ perform DC cardioversion w/o prior anticoagulation. Quinidine ♦ Hypotension ♦ Post cardioversion, maintain INR at 2-3 for 4 weeks ♦ Torsades de pointes ♦ Maintenance of sinus rhythm (Flecainide, propafenone, sotalol, amiodarone) Sotalol ♦ NOT for cardioversion ♦ Torsades de pointes ♦ Only for maintaining sinus rhythm ♦ CCF AF ♦ Exacerbation of COPD ♦ Electrical cardioversion: Unstable Stable o PT must be fasted and sedated, with good IV access and airway Mx o Check electrolyte and anticoagulation status ♦ Sync cardioversion Monophasic AF 200 joules, increments up to 360 joules ♦ 4 wks anticoagulation Atrial flutter 50 joules Biphasic AF 100 joules initially o Cxs: Thromboembolism, arrhythmia, myocardial injury, heart failure, skin burns. st 1 episode / Acute AF (<48hrs) Persistant / recurrent paroxysmal AF ♦ Other non-pharmacological rate control therapies♦ Pharm / electrical cardioversion w/o prior anticoagulation o Permanent Pacing♦ 4 wks anticoagulation o Catheter ablation – for PTs with paroxysmal AF due to atrial ectopics, PT with♦ long-term anticoagulation not necessary SVT or atrial flutter o Surgical ablation – “Maze” procedure: consider concomitant Sx ablation in PTs going for open heart Sx for valvular, ischaemic or congenital heart dz. Asymptomatic Symptomatic / complicated ♦ Maintenance of Sinus Rhythm ♦ Rate control ♦ Rate control & anticoagulation o Flecainide, propafenone and sotalol are first line drugs ♦ Long-term anticoagulation ♦ Cardioversion & maintain sinus rhythm o Amiodarone superior to previous drugs, but last choice of drug due to long term ♦ Long term anticoagulation extracardiac SE. • Treat ppt factor if present • Failure of drug therapy to achieve rate control or maintain sinus rhythm – consider pacemakers, defibrillator or catheter ablation
  • 3. o Choice of drug in heart dz: Heart failure: use amiodarone ♦ Contraindications to anticoagulation CAD: use sotalol ♦ Significant bleeding or fall risk ♦ PT unlikely to comply with diet & HPT with LVH ≥1.4cm: use amiodarone ♦ Recent surgery / trauma monitoring regimen ♦ Thrombocytopenia ♦ Active peptic ulcer dzRate Control:♦ Similar efficacy to rhythm control, but drugs used are safer and there is no problems ♦ Antithrombotic strategies wrt maintenance of sinus rhythm Any high-risk factors present Long-term oral anticoagulation (target INR2.5;♦ Pharmacological rate control: >60YO with one other range 2.0-3.0) Drug Comments SE moderate risk factor β-blockers ♦ First line Rx ♦ Bronchoconstriction. CI in <60YO + one moderate risk Either aspirin 100mg/day or warfarin depending on (propranolol, atenolol, ♦ Caution in PTs with heart asthma factor PT preference, risk of blding and access to sotalol) failure ♦ Heart failure 60-75YO with no risk factor anticoagulation monitoring ♦ Hypotension Male >75 with no risk factor ♦ Heart block Low risk or warfarin is CI Aspirin (100-300mg/day). Alternatives: ticlopidine, ♦ Bradycardia clopidogrel, dipyridamole CCB (verapamil, ♦ IV CCB useful in ♦ Hypotension <60YO with no risk factors & Long term aspirin or no Rx diltiazem) emergencies ♦ Heart block normal left atrial size ♦ Preferred over β-blockers ♦ Heart failure *always consider PT factors in determining target INR level (eg fall risk in elderly, recurrent in PT with COPD TE events despite anticoagulation, prosthetic heart valves) & modify Rx accordingly ♦ Caution in PTs with heart failure ♦ Monitoring: wkly INR initially, then 6-8wkly once INR stabilizes. Digoxin ♦ Good for PT with heart ♦ Digitalis toxicity ♦ Adjustment of warfarin dose: failure ♦ Heart block o after change in drugs that interact with warfarin (eg amiodarone) ♦ Caution in elderly and PT ♦ Bradycardia o surgery (stop warfarin for 5 days prior to surgery) with renal dysf(x) Amiodarone ♦ Good for PT with heart ♦ Thyroid dysfunction failure ♦ Hepatotoxicity ♦ Not first line due to SEs – ♦ Torsades de pointes require monitoring of LFT ♦ Warfarin & digoxin and TFT interaction *combination therapies are possible eg digoxin & β-blockers♦ Non-pharmacological rate control: Permanent pacing Digitally signed by DR WANA HLA SHWE DN: cn=DR WANA HLA SHWE, c=MY, AV nodal ablation & permanent pacing: o=UCSI University, School of Medicine, KT- Campus, Terengganu, ou=Internal Medicine Group, email=wunna.hlashwe@gmail.com Reason: This document is for UCSI year 4 students.Anticoagulation: Date: 2009.02.24 10:15:03 +0800♦ Prevent thromboembolic Cxs eg stroke & peripheral arterial thromboembolism♦ Risk factors High risk factors ♦ Prior stroke/ TIA/ systemic embolism ♦ Prosthetic heart valve ♦ Rheumatic mitral stenosis ♦ >75YO Moderate risk factors ♦ 60-75YO ♦ LVEF ≤35% ♦ HPT ♦ DM ♦ CCF ♦ Thyrotoxicosis ♦ Coronary artery dz Low risk factors ♦ <60YO